Purpose: To determine the incidence, mortality, stage, and recovery of acute kidney injury (AKI) in COVID-19 patients and further analyze the effect of patient demographics and comorbidities on AKI incidence. Study Design: Our study looked at 1545 charts of patients over 18 years old who presented to BronxCare Hospital in NY with a positive SARS-CoV-2 PCR test. Using the KDIGO criteria, any patient presenting with a creatinine of 1.5 times the baseline or that had an increase in creatinine of 0.3mg/dL in 48 hours was diagnosed with AKI. Pregnant patients, patients with end-stage renal disease (ESRD), and patients with a history of renal transplant were excluded. Results: The incidence of AKI in COVID-19 patients was 39% (608), and the mortality rate was 58.2% (354). Of the 254 survivors, 74.8% recovered. Moreover, 42.6% (259) of patients with AKI were admitted to the ICU. Twenty-six of our patients received hemodialysis during admission. There was a statistically significant association between AKI and age, race, hypertension (HTN), diabetes mellitus (DM), hepatitis C (HCV), congestive heart failure (CHF), CKD, patient outcome, and days spent in the hospital. Of the 608 patients with AKI, 294 (48.4%), 185 (30.4%) and 129 (21.2%) had AKI stage 1, 2 and 3, respectively. Conclusion: Early resource planning is necessary when admitting COVID-19 patients. Nephrology should be consulted early, and measures should be in place to optimize outpatient follow-up in the nephrology clinic. Lastly, the use of nephrotoxic agents should be carefully considered and, if possible, avoided from the time of admission in patients with COVID-19.
Purpose: To determine the incidence, mortality, stage, and recovery of acute kidney injury (AKI) in COVID-19 patients and further analyze the effect of patient demographics and comorbidities on AKI incidence. Study Design: Our study looked at 1545 charts of patients over 18 years old who presented to BronxCare Hospital in NY with a positive SARS-CoV-2 PCR test. Using the KDIGO criteria, any patient presenting with a creatinine of 1.5 times the baseline or that had an increase in creatinine of 0.3mg/dL in 48 hours was diagnosed with AKI. Pregnant patients, patients with end-stage renal disease (ESRD), and patients with a history of renal transplant were excluded. Results: The incidence of AKI in COVID-19 patients was 39% (608), and the mortality rate was 58.2% (354). Of the 254 survivors, 74.8% recovered. Moreover, 42.6% (259) of patients with AKI were admitted to the ICU. Twenty-six of our patients received hemodialysis during admission. There was a statistically significant association between AKI and age, race, hypertension (HTN), diabetes mellitus (DM), hepatitis C (HCV), congestive heart failure (CHF), CKD, patient outcome, and days spent in the hospital. Of the 608 patients with AKI, 294 (48.4%), 185 (30.4%) and 129 (21.2%) had AKI stage 1, 2 and 3, respectively. Conclusion: Early resource planning is necessary when admitting COVID-19 patients. Nephrology should be consulted early, and measures should be in place to optimize outpatient follow-up in the nephrology clinic. Lastly, the use of nephrotoxic agents should be carefully considered and, if possible, avoided from the time of admission in patients with COVID-19.
Authors: Ignacio Martin-Loeches; Elisabeth Papiol; Alejandro Rodríguez; Emili Diaz; Rafael Zaragoza; Rosa María Granada; Lorenzo Socias; Juan Bonastre; Montserrat Valverdú; Juan Carlos Pozo; Pilar Luque; Jose Antonio Juliá-Narvaéz; Lourdes Cordero; Antonio Albaya; Daniel Serón; Jordi Rello Journal: Crit Care Date: 2011-02-22 Impact factor: 9.097
Authors: Lili Chan; Kumardeep Chaudhary; Aparna Saha; Kinsuk Chauhan; Akhil Vaid; Shan Zhao; Ishan Paranjpe; Sulaiman Somani; Felix Richter; Riccardo Miotto; Anuradha Lala; Arash Kia; Prem Timsina; Li Li; Robert Freeman; Rong Chen; Jagat Narula; Allan C Just; Carol Horowitz; Zahi Fayad; Carlos Cordon-Cardo; Eric Schadt; Matthew A Levin; David L Reich; Valentin Fuster; Barbara Murphy; John C He; Alexander W Charney; Erwin P Böttinger; Benjamin S Glicksberg; Steven G Coca; Girish N Nadkarni Journal: J Am Soc Nephrol Date: 2020-09-03 Impact factor: 10.121
Authors: Ian A Strohbehn; Sophia Zhao; Harish Seethapathy; Meghan Lee; Nifasha Rusibamayila; Andrew S Allegretti; Xavier Vela Parada; Meghan E Sise Journal: Kidney Int Rep Date: 2021-07-15
Authors: James Nugent; Abinet Aklilu; Yu Yamamoto; Michael Simonov; Fan Li; Aditya Biswas; Lama Ghazi; Jason Greenberg; Sherry Mansour; Dennis Moledina; F Perry Wilson Journal: JAMA Netw Open Date: 2021-03-01